Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis

Arrowhead Pharmaceuticals is a clinical- and commercial-stage biotechnology company developing genetic medicines through its TRiM RNAi delivery platform. Its first approved product, REDEMPLO (plozasiran), targets ApoC3 and was approved by the FDA in November 2025 for FCS. The investment case depends on expanding the product into sHTG, a much larger market, while advancing wholly owned and partnered cardiovascular, obesity, MASH, pulmonary, and CNS programs. **The principal catalyst is the expected sHTG sNDA before year-end 2026**, supported by a Priority Review Voucher that could accelerate approval to mid-2027. In fiscal Q3 2026, revenue increased 171.0% year over year to $75.25 million and exceeded consensus by approximately 104%, although R&D spending of $198.22 million drove a GAAP net loss of $194.28 million, or $(1.36) per diluted share. The company held $1.57 billion of cash resources at June 30, 2026, but trades at approximately 19.32x–19.48x trailing sales and remains unprofitable. Analysts remain constructive, with 9 of 13 covering analysts rating the stock Buy, average targets of $96.92, and recent targets of $120–$126. The stock offers substantial upside if sHTG adoption and pipeline execution exceed expectations, but the valuation and Ionis patent litigation create meaningful downside.